阿扎司琼注射液预防芬太尼透皮贴剂所致的肿瘤患者恶心呕吐的疗效观察
Azasetron Prevents of Nausea and Vomiting Caused by Transdermal Fentanyl in Cancer Patients
-
摘要: 目的 观察阿扎司琼注射液对芬太尼透皮贴剂所致的肿瘤患者恶心呕吐的预防作用。 方法将140例中重度癌痛患者随机分为试验组(70例)和对照组(70例)。两组均接受芬太尼透皮贴剂止痛治疗。试验组在使用芬太尼透皮贴剂第一周时,每日同时予以阿扎司琼注射液静脉滴注。对照组单纯予以芬太尼透皮贴剂治疗。连续两周观察患者在止痛治疗中恶心、呕吐的情况。结果(1)实验组患者第一周恶心及呕吐的发生概率及严重程度较对照组有明显改善,其差异有统计学意义。两组患者第二周恶心呕吐发生概率未见明显差异。(2)对照组患者第一周恶心及呕吐情况较第二周严重,其差异有统计学意义。试验组患者第一周和第二周之间恶心呕吐情况未见明显差异。结论阿扎司琼注射液可以有效预防芬太尼帖剂所致的恶心呕吐等不良反应。Abstract: Objective To study the efficacy of Azasetron in prevention of transdermal fentanyl induced nausea and vomiting in cancer patients. Methods One hudred and forty patients with the moderate-severe cancer-related pain were randomly divided into test group(70 patients) and control group(70 patients).Transdermal fentanyl and Azasetron were given to test group in the first week and transdermal fentanyl alone to control group.The side effects of transdermal fentanyl,including nausea and vomiting,were observed within at least 2 weeks. Results (1)The incidence and intensity of nausea and vomiting in the test group were significantly lower than those in the control group during the first week.As to the second week,there was no significant difference between two groups.(2)The patients in the control group had more severe nausea and vomiting in the first week than those in the following week with a significant difference.No significant difference was found in test group between the first and second week. Conclusion Azasetron could effectively prevent the nausea and vomiting caused by transdermal fentanyl in cancer patients.